# Israeli 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation

> **NCT00205907** · PHASE1,PHASE2 · TERMINATED · sponsor: **Aeris Therapeutics** · enrollment: 4 (actual)

## Conditions studied

- Pulmonary Emphysema

## Interventions

- **BIOLOGICAL:** BLVR Hydrogel

## Key facts

- **NCT ID:** NCT00205907
- **Lead sponsor:** Aeris Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-01
- **Primary completion:** 2006-08
- **Final completion:** 2007-04
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Change in Formulation
- **Last updated:** 2008-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00205907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00205907, "Israeli 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00205907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*